FINDLAY, OH - January 20, 2026 - PRESSADVANTAGE - Dr. Andrea Adams-Miller of TheREDCarpetConnection.com, LLC, reacts to ...

A measure of brain complexity, derived from magnetic stimulation and EEG, can effectively evaluate conscious processing in ...

A popular technique for studying brain disorders, known as lesion network mapping (LNM), appears to have a fundamental ...

Supervisor, integrates neuroscience-informed psychotherapy with clinical expertise to support individuals struggling with ...

The CANLab was founded in 2006 when Dr. Kensinger arrived at Boston College, becoming one of the first laboratories at BC to use cognitive neuroscience methods to understand human behavior. Since then ...

– Issued and pending claims expected to protect ALTO-207 into the mid-2040s – Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of ...

Alto Neuroscience, Inc. (ANRO) has received a new Buy rating, initiated by Robert W. Baird analyst, Brian Skorney. Brian Skorney has given his Buy rating due to a combination of factors including Alto ...

Despite countless programmes and initiatives, rates of entrepreneurial intention — a marker of how willing people are to start new ventures — remains stagnant. But what if the secrets to ...

MOUNTAIN VIEW, Calif. - Alto Neuroscience, Inc. (NYSE:ANRO) announced the issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207, a novel combination of ...

– Issued and pending claims expected to protect ALTO-207 into the mid-2040s – MOUNTAIN VIEW, Calif., January 14, 2026--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage ...